PHARMA’S ALMANAC: Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer, Elicio Therapeutics. “As an oncologist, waiting with patients who’d undergone chemotherapy and surgery for mKRAS-driven tumors to see if they’d relapse left me feeling helpless — I wanted to do more than wait and see. “